Brief: Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma

Erasca

18/06/2024 13:12

June 18 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA INITIATES SEACRAFT-2 PIVOTAL PHASE 3 TRIAL
EVALUATING
NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH NRAS-MUTANT
MELANOMA
    * ERASCA INC - RANDOMIZED STAGE 1 READOUT FOR NAPORAFENIB
PLUS
TRAMETINIB VERSUS. TRAMETINIB MONOTHERAPY EXPECTED IN 2025
    * ERASCA INC - FAVORABLE MOS AND MPFS DEMONSTRATED IN POOLED
ANALYSIS OF PHASE 1B AND PHASE 2 TRIALS IN NRASM MELANOMA

Source text for Eikon:  ID:nGNXbxSbGD 
Further company coverage:  ERAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))